Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Publication year range
1.
Clin Transl Oncol ; 11(1): 48-53, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19155204

ABSTRACT

OBJECTIVES: To evaluate the initial response and outcomes (quality of life and presence of side effects) in patients with advanced neuroendocrine tumours (NET) after treatment with radiolabelled somatostatin analogues: (90)Y-DOTATyr3- octreotide ((90)Y-DOTATOC) and (177)Lu-DOTA-Tyr3- octreotate ((177)Lu-DOTATATE). MATERIAL AND METHODS: The study included 5 patients with advanced NET referred to European centres for treatment with (90)Y-DOTATOC and (177)Lu-DOTATATE after lack of response to conventional treatment. The mean age was 45.6 years (29-68 years). Response to therapy was assessed according to: (1) RECIST criteria, as complete response, partial response, stable disease or disease progression, (2) post-treatment survival time and (3) quality of life, using the Karnofsky performance index. RESULTS: All patients survived for >20 months after treatment; mean survival time was 28 months. At the time of writing, three of the patients are alive after 20, 26 and 37 months. Partial response was observed in one patient, stable disease in three and disease progression in the fifth patient. A good-to-excellent post-treatment quality of life was observed in all patients. CONCLUSION: Therapy with radiolabelled somatostatin analogues showed promising results in patients with advanced NET, with a partial response or disease stabilisation in four of the five patients, who have enjoyed an extended survival period and an improved quality of life.


Subject(s)
Antineoplastic Agents/therapeutic use , Neuroendocrine Tumors/radiotherapy , Octreotide/analogs & derivatives , Organometallic Compounds/therapeutic use , Adult , Aged , Female , Humans , Male , Middle Aged , Neuroendocrine Tumors/mortality , Octreotide/therapeutic use , Quality of Life , Somatostatin/analogs & derivatives , Treatment Outcome
2.
Rev Esp Med Nucl ; 22(5): 336-9, 2003.
Article in Spanish | MEDLINE | ID: mdl-14534009

ABSTRACT

Clear cell sarcoma of the soft parts (CCSSP) is a rare and highly malignant tumor. This is a case report of a 31 years old woman who presented with a tumor in the internal face of left thigh. The tumor biopsy was suggestive of a possible malignant tumor of the peripheral nerve sheath (malignant schwannoma). Biochemical analyses, computed tomography and magnetic resonance were performed and reported a sarcoma of soft parts (CCSSP) without abnormal inguinal lymph nodes. With this diagnostic suspicion, the patient was sent to the Nuclear Medicine Service of our center where a 201Thallium scintigraphy study was performed. In this study, it showed the primary tumor together with a hot spot in the homolateral inguinal region, suggestive of the presence of a metastastic lymph node. This finding would change the surgical attitude in the patient, including inguinal lymphadenectomy. The post-surgical histological study confirmed a clear cell sarcoma of soft parts (CCSSP) with a metastatic inguinal lymph node.


Subject(s)
Radiopharmaceuticals , Sarcoma, Clear Cell/diagnostic imaging , Soft Tissue Neoplasms/diagnostic imaging , Tendons/diagnostic imaging , Thallium Radioisotopes , Adult , Diagnosis, Differential , Female , Humans , Lymphatic Metastasis , Magnetic Resonance Imaging , Neurilemmoma/diagnostic imaging , Radionuclide Imaging , Sarcoma, Clear Cell/diagnosis , Soft Tissue Neoplasms/diagnosis , Thallium , Thigh , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL